KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Operating Leases (2019 - 2025)

Idexx Laboratories has reported Operating Leases over the past 7 years, most recently at $101.2 million for Q4 2025.

  • Quarterly results put Operating Leases at $101.2 million for Q4 2025, up 3.39% from a year ago — trailing twelve months through Dec 2025 was $101.2 million (up 3.39% YoY), and the annual figure for FY2025 was $101.2 million, up 3.39%.
  • Operating Leases for Q4 2025 was $101.2 million at Idexx Laboratories, down from $106.5 million in the prior quarter.
  • Over the last five years, Operating Leases for IDXX hit a ceiling of $124.4 million in Q3 2024 and a floor of $78.2 million in Q1 2021.
  • Median Operating Leases over the past 5 years was $104.7 million (2024), compared with a mean of $105.2 million.
  • Biggest five-year swings in Operating Leases: soared 40.93% in 2022 and later fell 14.38% in 2025.
  • Idexx Laboratories' Operating Leases stood at $87.4 million in 2021, then grew by 15.86% to $101.2 million in 2022, then decreased by 1.55% to $99.7 million in 2023, then fell by 1.84% to $97.8 million in 2024, then grew by 3.39% to $101.2 million in 2025.
  • The last three reported values for Operating Leases were $101.2 million (Q4 2025), $106.5 million (Q3 2025), and $107.6 million (Q2 2025) per Business Quant data.